Zobrazeno 1 - 7
of 7
pro vyhledávání: '"K S, Filonenko"'
Autor:
I. A. Kriachok, O. I. Novosad, I. V. Pastushenko, T. V. Skrypets, O. I. Gorbach, T. V. Kadnikova, I. B. Tytorenko, E. V. Kushchevyy, K. O. Ulianchenko, K. S. Filonenko, Y. A. Stepanishyna, Y. V. Kmetyuk, O. O. Karpova, L. V. Mykhalska, O. M. Kindrakevych, G. V. Pylypenko, E. V. Lukjanec, V. D. Duma, V. P. Kozlov, U. V. Kozlov, N. V. Strembitska, L. P. Batyuk, O. V. Ryzhak, M. M. Chupryna, H. I. Chikalova, N. E. Novikov, V. G. Kosinova, E. G. Oliinichenko, O. I. Lola, A. V. Kholodna, O. B. Loza
Publikováno v:
Likarska sprava. :63-70
In recent years, treatment approaches in patients with HL are actively discussed. The actual issue remains the combination therapy or possible avoiding of radiation therapy to reduce toxicity and the occurrence of secondary tumors in the future. In a
Publikováno v:
Likarska sprava. :9-19
Дифузна В-великоклітинна лімфома (ДВВКЛ) належить до потенційно виліковних захворювань. Проте група хворих на ДВВКЛ є дуже різнорідною
Autor:
I. А. Kryachok, I. A. Stepanishyna, I. B. Titorenko, O. I. Novosad, K. S. Filonenko, A. V. Martynchyk, T. V. Kadnikova, O. M. Aleksik, Е. V. Kuschevyy, null I. V., K. O. Ulyanchenko, T. V. Skrypets
Publikováno v:
Likarska sprava. :16-22
Представлены данные литературы о диагностике и различных подходах к терапии первой линии первичной медиастинальной В-крупноклеточной
Autor:
L A, Syvak, H O, Hubareva, K S, Filonenko, N M, Majdanevych, O M, Aleksyk, S A, Lyalkin, M J, Klimanov, A V, Askolskyi, N V, Kasap
Publikováno v:
Likars'ka sprava. (3-4)
The use of modern chemotherapy (CT) allowed to achieve significant progress in the treatment of many malignant tumors that were previously considered fatal. Improving the efficiency of the treatment was achieved by the intensification of chemotherapy
Autor:
O I, Novosad, I A, Kriachok, T V, Kadnikova, K S, Filonenko, I B, Tytorenko, A V, Martynchyk, O M, Aleksyk, Iu O, Gusachenko, I A, Filonenko
Publikováno v:
Likars'ka sprava. (3-4)
Achievements of world practice about development and prophilaxis of tromboembolic events (VTE) in cancer patients. Particular attention is paid to prevention of VTE in patients with multiply myeloma who receive chemotherapy with Thalidomide.
Autor:
I A, Kriachok, K S, Filonenko, G O, Gubareva, I B, Tytorenko, O I, Novosad, T V, Kadnikova, O M, Aleksik, A V, Martynchyk, É V, Kushchevyĭ, Ia V, Pastushenko, L B, Kutsenko
Publikováno v:
Likars'ka sprava. (1-2)
Management of non-Hodgkin's lymphomas (NHL) has been significantly changed during last 40 years from radiotherapy to modern polychemotherapy with application of monoclonal antibodies. A ten year experience of the treatment of patients with B-cell NHL
Autor:
H O, Hubareva, I A, Kriachok, I B, Tytorenko, O M, Aleksyk, O I, Novosad, T V, Kadnikova, A V, Martynchyk, Ia V, Pastushenko, K S, Filonenko, Ie V, Kushchevyĭ
Publikováno v:
Likars'ka sprava. (1-2)
The treatment of patients with refractory forms of Hodgkin's lymphomas in combination with chemo-radiotherapy is priority. Nevertheless, chemotherapy has to include multicomponent schemes and radiation therapy should be an addition and consolidative